^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MET amplification

    i
    Entrez ID:
    4233
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer (NRG-LU003) (NCT03737994)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    07/25/2019
    Primary completion :
    07/21/2021
    Completion :
    12/02/2025
    MET
    |
    ALK positive • MET amplification • ALK rearrangement
    |
    cisplatin • Xalkori (crizotinib) • carboplatin • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Ensacove (ensartinib) • Pemfexy (pemetrexed)
    A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) (NCT03940703)
    Phase 2
    EMD Serono Research & Development Institute, Inc.
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    09/19/2019
    Primary completion :
    05/11/2023
    Completion :
    10/31/2025
    EGFR • MET
    |
    EGFR mutation • MET amplification
    |
    Tagrisso (osimertinib) • Tepmetko (tepotinib)
    Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab (M21-404) (NCT05029882)
    Phase 1
    AbbVie
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    10/13/2021
    Primary completion :
    11/01/2025
    Completion :
    11/01/2025
    MET
    |
    MET amplification • EGFR wild-type
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • telisotuzumab adizutecan (ABBV-400)
    Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) (LUNG-MAP SUB-STUDY) (NCT06116682)
    Phase 2
    SWOG Cancer Research Network
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    11/19/2024
    Primary completion :
    05/31/2028
    Completion :
    05/31/2028
    EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK
    |
    BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • MET amplification • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement
    |
    Rybrevant (amivantamab-vmjw) • amivantamab SC (Ami-LC)
    Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors (NCT03598244)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    11/27/2018
    Primary completion :
    06/01/2026
    Completion :
    06/01/2028
    MET
    |
    MET amplification
    |
    Orpathys (savolitinib)
    Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer (KisMET-01) (NCT05652868)
    Phase 1
    Mythic Therapeutics
    Recruiting
    Last update posted :
    02/12/2025
    Initiation :
    03/23/2023
    Primary completion :
    12/01/2025
    Completion :
    12/01/2027
    MET
    |
    MET amplification • MET exon 14 mutation
    |
    MYTX-011
    Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS) (NCT02609776)
    Phase 1
    Janssen Research & Development, LLC
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    05/24/2016
    Primary completion :
    01/31/2024
    Completion :
    06/30/2025
    ALK • MET
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • MET expression • EGFR exon 20 mutation • EGFR positive
    |
    carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
    PLATFORM Study of Precision Medicine for Rare Tumors (NCT04423185)
    Phase 2
    Cancer Institute and Hospital, Chinese Academy ...
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    08/15/2020
    Primary completion :
    07/01/2026
    Completion :
    07/01/2028
    EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A
    |
    BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification
    |
    Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)
    Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib (SAVANNAH) (NCT03778229)
    Phase 2
    AstraZeneca
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    01/09/2019
    Primary completion :
    08/23/2024
    Completion :
    05/28/2025
    EGFR • MET
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR amplification • MET overexpression
    |
    Tagrisso (osimertinib) • Orpathys (savolitinib)
    A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC (CoC) (NCT04606771)
    Phase 2
    AstraZeneca
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    09/28/2020
    Primary completion :
    12/21/2022
    Completion :
    03/28/2025
    MET
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification
    |
    Tagrisso (osimertinib) • Orpathys (savolitinib)
    Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations (NCT05567055)
    Phase 2
    Timothy Burns, MD, PHD
    Withdrawn
    Last update posted :
    06/17/2024
    Initiation :
    10/03/2023
    Primary completion :
    09/01/2026
    Completion :
    09/01/2028
    MET
    |
    MET amplification
    |
    Tabrecta (capmatinib)
    Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) (Lung-MAP Sub-Study) (NCT05642572)
    Phase 2
    SWOG Cancer Research Network
    Recruiting
    Last update posted :
    06/11/2024
    Initiation :
    05/05/2023
    Primary completion :
    05/31/2026
    Completion :
    05/31/2027
    EGFR • MET
    |
    EGFR mutation • MET amplification
    |
    Tagrisso (osimertinib) • Cyramza (ramucirumab) • Tabrecta (capmatinib)
    A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521 (BYON3521.001) (NCT05323045)
    Phase 1
    Byondis B.V.
    Active, not recruiting
    Last update posted :
    06/07/2024
    Initiation :
    03/21/2022
    Primary completion :
    07/01/2024
    Completion :
    07/01/2024
    MET
    |
    MET amplification • MET mutation • MET expression • MET positive
    |
    BYON3521
    Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial (NCT04693468)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    12/01/2020
    Primary completion :
    09/03/2025
    Completion :
    09/03/2025
    ALK • MET • BRCA1 • BRCA2 • ROS1 • RAD51C • RAD51D
    |
    MET amplification • MET mutation • MET expression • ALK translocation
    |
    Xalkori (crizotinib) • Ibrance (palbociclib) • Talzenna (talazoparib) • Inlyta (axitinib)
    The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC (NCT06109558)
    Phase 1/2
    Hunan Province Tumor Hospital
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    12/31/2023
    Primary completion :
    12/30/2026
    Completion :
    07/30/2027
    EGFR • MET • RET
    |
    MET amplification • RET fusion • EGFR T790M negative
    |
    Tagrisso (osimertinib)
    Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS). (NCT05219162)
    Phase 4
    AstraZeneca
    Completed
    Last update posted :
    05/21/2024
    Initiation :
    02/25/2022
    Primary completion :
    05/09/2024
    Completion :
    05/09/2024
    EGFR • MET
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification
    |
    Tagrisso (osimertinib)
    Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer (PULSE) (NCT03992456)
    Phase 2
    Academic and Community Cancer Research United
    Active, not recruiting
    Last update posted :
    05/21/2024
    Initiation :
    04/24/2020
    Primary completion :
    12/01/2023
    Completion :
    10/07/2024
    EGFR • HER-2 • KRAS • BRAF • PIK3CA • MET • NRAS • MSI • PTEN • CD73 • TGFA
    |
    KRAS mutation • EGFR mutation • MSI-H/dMMR • HER-2 amplification • PIK3CA mutation • MET amplification • KRAS wild-type • NRAS wild-type
    |
    Vectibix (panitumumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)
    Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors (ADVL1622) (NCT02867592)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    05/18/2017
    Primary completion :
    06/30/2021
    Completion :
    09/21/2024
    MET • RET • AXL
    |
    MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA) (NCT03175224)
    Phase 2
    Apollomics Inc.
    Recruiting
    Last update posted :
    05/10/2024
    Initiation :
    09/27/2017
    Primary completion :
    03/30/2026
    Completion :
    11/30/2026
    HGF • PTPRZ1
    |
    EGFR mutation • MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET expression • EGFR positive • MET fusion
    |
    bozitinib (APL-101) • CBT101
    PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer (NCT06083857)
    Phase 1/2
    M.D. Anderson Cancer Center
    Not yet recruiting
    Last update posted :
    05/02/2024
    Initiation :
    04/30/2024
    Primary completion :
    12/31/2025
    Completion :
    12/31/2027
    MET
    |
    MET amplification • MET exon 14 mutation • MET overexpression
    |
    Rybrevant (amivantamab-vmjw) • Tepmetko (tepotinib)
    A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (NCT05513703)
    Phase 2
    AbbVie
    Active, not recruiting
    Last update posted :
    04/15/2024
    Initiation :
    11/21/2022
    Primary completion :
    03/18/2025
    Completion :
    03/31/2026
    MET
    |
    MET amplification
    |
    telisotuzumab vedotin (ABBV-399)
    Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients (TOTEM) (NCT04772235)
    Phase 1
    Instituto Oncológico Dr Rosell
    Recruiting
    Last update posted :
    04/03/2024
    Initiation :
    02/11/2022
    Primary completion :
    04/01/2026
    Completion :
    06/01/2026
    ALK • MET • ROS1 • HAVCR2 • NTRK
    |
    EGFR mutation • MET amplification • EGFR T790M
    |
    Tagrisso (osimertinib) • Augtyro (repotrectinib)
    A Study of Amivantamab in People With Esophagogastric Cancer (NCT05117931)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    03/06/2024
    Initiation :
    12/02/2021
    Primary completion :
    11/01/2025
    Completion :
    11/01/2025
    HER-2
    |
    MET amplification • EGFR amplification
    |
    Rybrevant (amivantamab-vmjw)
    REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer (NCT04077099)
    Phase 1/2
    Regeneron Pharmaceuticals
    Active, not recruiting
    Last update posted :
    03/06/2024
    Initiation :
    01/07/2020
    Primary completion :
    10/20/2024
    Completion :
    10/20/2024
    MET
    |
    MET amplification • MET exon 14 mutation • MET mutation • MET expression • MET elevation
    |
    davutamig (REGN5093)
    Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC (SOUND) (NCT05374603)
    Phase 2
    AstraZeneca
    Suspended
    Last update posted :
    03/01/2024
    Initiation :
    11/23/2022
    Primary completion :
    10/31/2024
    Completion :
    12/31/2024
    EGFR • MET
    |
    MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET mutation
    |
    Imfinzi (durvalumab) • Orpathys (savolitinib)
    To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation (NCT04052971)
    Phase 1
    Abion Inc
    Recruiting
    Last update posted :
    02/19/2024
    Initiation :
    08/01/2019
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    MET
    |
    MET amplification • MET exon 14 mutation • MET overexpression
    |
    vabametkib (ABN401)
    Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC (FLOWERS) (NCT05163249)
    Phase 2
    Guangdong Association of Clinical Trials
    Active, not recruiting
    Last update posted :
    02/09/2024
    Initiation :
    05/31/2022
    Primary completion :
    04/01/2024
    Completion :
    08/01/2026
    MET
    |
    EGFR mutation • MET amplification • MET overexpression • MET expression
    |
    Tagrisso (osimertinib) • Orpathys (savolitinib)
    CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen (NCT05312398)
    Phase 2
    University of Campania "Luigi Vanvitelli&q...
    Active, not recruiting
    Last update posted :
    02/01/2024
    Initiation :
    07/15/2021
    Primary completion :
    08/15/2025
    Completion :
    06/15/2026
    HER-2 • BRAF • MET • PTEN • RAS
    |
    HER-2 amplification • HER-2 expression • MET amplification • BRAF wild-type • RAS mutation • MET mutation
    |
    Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer (NCT04311034)
    Phase 1/2
    RemeGen Co., Ltd.
    Completed
    Last update posted :
    12/18/2023
    Initiation :
    09/26/2018
    Primary completion :
    12/21/2021
    Completion :
    05/30/2022
    HER-2 • MET
    |
    EGFR mutation • HER-2 overexpression • HER-2 mutation • MET amplification • EGFR T790M • MET mutation • HER-2 exon 20 mutation
    |
    Aidixi (disitamab vedotin)
    Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC (Geometry-N) (NCT04926831)
    Phase 2
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    12/14/2023
    Initiation :
    08/10/2022
    Primary completion :
    08/06/2026
    Completion :
    08/06/2026
    MET
    |
    MET amplification • MET exon 14 mutation • MET mutation
    |
    Tabrecta (capmatinib)
    Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (SHIELD-1) (NCT03993873)
    Phase 1/2
    Turning Point Therapeutics, Inc.
    Active, not recruiting
    Last update posted :
    11/20/2023
    Initiation :
    09/21/2019
    Primary completion :
    03/02/2025
    Completion :
    03/02/2025
    MET
    |
    MET amplification • MET exon 14 mutation • MET mutation • MET fusion
    |
    elzovantinib (TPX-0022)
    Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment (NCT06106802)
    Phase 2
    Samsung Medical Center
    Not yet recruiting
    Last update posted :
    10/30/2023
    Initiation :
    02/02/2024
    Primary completion :
    09/30/2029
    Completion :
    09/30/2029
    EGFR • BRAF • MET
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR C797S • EGFR mutation + MET-CEP7 fusion
    |
    Tepmetko (tepotinib) • Lazcluze (lazertinib)
    Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer (NCT03468985)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    10/17/2023
    Initiation :
    05/07/2018
    Primary completion :
    05/09/2022
    Completion :
    12/21/2022
    EGFR • PD-L1 • ALK • RET • ROS1
    |
    EGFR L858R • EGFR exon 19 deletion • MET amplification • ALK rearrangement • MET exon 14 mutation • EGFR L861Q • EGFR G719X • RET rearrangement • EGFR negative
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    ctDNA Guided Treatment of Early Resistance to Targeted Treatment (TATIN) (NCT04148066)
    Phase N/A
    The Netherlands Cancer Institute
    Completed
    Last update posted :
    10/09/2023
    Initiation :
    07/17/2019
    Primary completion :
    12/17/2021
    Completion :
    12/17/2021
    EGFR • MET
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification
    |
    Xalkori (crizotinib) • Tagrisso (osimertinib)
    Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer (NCT06067776)
    Phase 1
    Jonathan Riess
    Not yet recruiting
    Last update posted :
    10/05/2023
    Initiation :
    01/01/2024
    Primary completion :
    01/01/2025
    Completion :
    11/01/2026
    HER-2 • BRAF • ALK • MET • RET
    |
    EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • MET amplification • EGFR T790M • RET fusion • HER-2 exon 20 insertion • ALK fusion • EGFR L861Q • RAS mutation • EGFR G719X • EGFR S768I • HER-2 exon 20 mutation • BRAF amplification • HER-2 exon 23 mutation
    |
    Erbitux (cetuximab) • Tagrisso (osimertinib) • Tukysa (tucatinib)
    EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers (NCT05176665)
    Phase 1/2
    Shanghai EpimAb Biotherapeutics Co., Ltd.
    Recruiting
    Last update posted :
    09/29/2023
    Initiation :
    10/21/2021
    Primary completion :
    08/04/2024
    Completion :
    08/31/2024
    EGFR • KRAS • BRAF • ALK • NRAS • ROS1 • FGFR • NTRK
    |
    KRAS mutation • BRAF mutation • NRAS mutation • MET amplification • EGFR amplification • EGFR overexpression
    |
    bafisontamab (EMB-01)
    Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers (NCT04712877)
    Phase N/A
    Lung Cancer Mutation Consortium
    Recruiting
    Last update posted :
    09/12/2023
    Initiation :
    06/15/2022
    Primary completion :
    06/15/2024
    Completion :
    06/15/2025
    EGFR • HER-2 • BRAF • ALK • TMB • MET • RET • ROS1 • NTRK
    |
    BRAF V600E • EGFR mutation • HER-2 amplification • BRAF V600 • MET amplification • ALK rearrangement • MET exon 14 mutation • RET mutation • ROS1 rearrangement • MET mutation • RET rearrangement • MET amplification + MET Exon 14 mutation